EMMANUEL NWAPA: Open Payments
NPI 1922107788 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,619 in 82 payments from 16 companies in 2025. Trend: 2023 $651 · 2024 $919 · 2025 $1,619
Food & beverage: $1,619
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $270 |
| Otsuka America Pharmaceutical, Inc. | 11 | $233 |
| Collegium Pharmaceutical, Inc. | 12 | $190 |
| Neurocrine BioSciences, Inc. | 7 | $184 |
| E.R. Squibb & Sons, L.L.C. | 9 | $149 |
| ABBVIE INC. | 6 | $135 |
| Janssen Pharmaceuticals, Inc | 3 | $94 |
| Teva Pharmaceuticals USA, Inc. | 4 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Almatica Pharma LLC | 2 | $51 |
Products named: ARISTADA, Jornay PM, REXULTI, INGREZZA, COBENFY, VRAYLAR, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across NV — which companies pay providers there.
